Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma

Ipilimumab for previously treated advanced (unresectable or metastatic) malignant melanoma. NICE technology appraisal guidance 268 (2012).

Skin cancer prevention: information, resources and environmental changes. NICE public health guidance 32 (2011).

Improving outcomes for people with skin tumours including melanoma. NICE cancer service guidance (2006).

Referral guidelines for suspected cancer. NICE clinical guideline 27 (2005).

Improving supportive and palliative care for adults with cancer. NICE cancer service guidance (2004).

Ipilimumab in combination with dacarbazine for previously untreated unresectable stage III or IV malignant melanoma (expected date of publication August 2013).